FeesSafety
Pluang+

Praxis Precision Medicines rated Strong Buy with $601 fair value, FDA decision on key drug in January is pivotal.

Analyst Insights
16 Nov 2026, 11:21 WIB
Seeking Alpha
View Source
Bullish
Praxis Precision Medicines rated Strong Buy with $601 fair value, FDA decision on key drug in January is pivotal.

Analyst Zbigniew Budzinski maintains a Strong Buy rating on Praxis Precision Medicines with a fair value of $601 per share, which is 85% above the recent closing price. The valuation was adjusted down from $664 mainly due to correcting the share count and lower net cash. The upcoming FDA decision in January on the drug Ulixacaltamide is the main risk factor, with approval potentially raising value to $679 or dropping it to $159 if rejected. Additional upside may come from the EMERALD program, though initial sales could face payer access challenges expected to improve over several months.

Praxis Precision Medicines is the subject of this update, provided here with Pluang's Health sector market data for context. For readers following Health stocks, as of Nov 16, 2026 15:41 WIB, out of 150 priced US Health-sector stocks on Pluang, 60 rose and 86 fell. Among notable movers, ClearPoint Neuro Inc (CLPT) dropped 7.52% to USD 8.48 with a typical hold time of 13 days, Tilray Brands Inc (TLRY) declined 7.28% to USD 2.42 with a 33-day hold, and Definium Therapeutics Inc (DFTX) fell 7.19% to USD 31.99 with a 20-day hold.

More News

Credit Agricole Toulouse 31 reports weekly transactions on cooperative investment certificates.

Credit Agricole Toulouse 31 reports weekly transactions on cooperative investment certificates.

Credit Agricole Toulouse 31 disclosed its weekly transactions on cooperative investment certificates (CCI) for the period from November 9 to November 13, 2026. The report details daily volumes and average acquisition prices, showing active buybacks o...

Market News
Neutral
18 minutes ago
Euronet and Getnet integrate VAT refund into payment terminals for smoother Tax Free shopping in Spain.

Euronet and Getnet integrate VAT refund into payment terminals for smoother Tax Free shopping in Spain.

Euronet and Getnet, Santander Group's payment platform, have partnered to integrate VAT refund services directly into payment terminals in Spain. This collaboration allows merchants to process Tax Free transactions seamlessly at the point of sale, si...

Market News
Bullish
18 minutes ago
Danske Bank buys back 25,000 shares in week 46, continuing its DKK 4.5 billion buy-back program.

Danske Bank buys back 25,000 shares in week 46, continuing its DKK 4.5 billion buy-back program.

Danske Bank executed transactions to repurchase 25,000 shares during week 46 as part of its ongoing share buy-back program announced in February 2026. The program targets a total buy-back of up to DKK 4.5 billion or 45 million shares by January 2027....

Company Fundamentals
Neutral
1 hour ago
French firms boost AI-driven cybersecurity, focusing on productivity and operational results over processes.

French firms boost AI-driven cybersecurity, focusing on productivity and operational results over processes.

A new study by Securonix shows French organizations are increasingly adopting AI-driven cybersecurity operations, prioritizing productivity and measurable outcomes rather than just processes. French firms lead in allowing AI to automatically trigger ...

Market News
Neutral
2 hours ago
Lakefront Biotherapeutics launches new €50M share buyback after completing initial program

Lakefront Biotherapeutics launches new €50M share buyback after completing initial program

Lakefront Biotherapeutics has started a new €50 million share buyback program following the completion of its initial €50 million program, in which it repurchased about 1.99 million shares. The new program, running until March 31, 2027, aims to enhan...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App